# Zoledronic acid for chronic kidney disease–associated osteoporosis

**Authors:** Sukanya Sakthivel, Krista Dybtved Kjærgaard, Per Ivarsen, Bente Langdahl, Hanne Skou Jørgensen

PMC · DOI: 10.1007/s11657-026-01680-2 · Archives of Osteoporosis · 2026-02-25

## TL;DR

This paper discusses the use of zoledronic acid in a patient with chronic kidney disease and osteoporosis, showing potential benefits and the need for further research.

## Contribution

The paper presents a case demonstrating the potential efficacy and safety of zoledronic acid in treating osteoporosis in chronic kidney disease patients.

## Key findings

- Zoledronic acid was well-tolerated in a patient with chronic kidney disease.
- The treatment provided clinical improvement in bone fragility.
- The case suggests a need for trials on anti-resorptive drugs in this patient population.

## Abstract

Patients with chronic kidney disease have a high risk of fracture, but evidence-based treatment protocols for osteoporosis are lacking. Bisphosphonates are commonly used anti-resorptive drugs, but due to renal excretion, patients with chronic kidney disease have not been included in clinical trials.

We present a case of severe bone fragility in a patient on long-term hemodialysis therapy where zoledronate was well-tolerated and provided clinical improvement.

This case highlights the potential role of bisphosphonates in chronic kidney disease–associated osteoporosis and the need for trials to establish the safety and efficacy of anti-resorptive drugs in this patient population.

## Linked entities

- **Chemicals:** Zoledronic acid (PubChem CID 68740)
- **Diseases:** chronic kidney disease (MONDO:0005300), osteoporosis (MONDO:0005298)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, ALPP (alkaline phosphatase, placental) [NCBI Gene 250] {aka ALP, PALP, PLAP, PLAP-1}, PTH (parathyroid hormone) [NCBI Gene 5741] {aka FIH1, PTH1}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}
- **Diseases:** polycystic kidney disease (MESH:D007690), femoral fractures (MESH:D005264), chronic (MESH:D002908), kidney injury (MESH:D007674), breast cancer (MESH:D001943), cardiovascular disease (MESH:D002318), hypophosphatemia (MESH:D017674), calciphylaxis (MESH:D002115), vertebral fracture (MESH:C535781), ischemic heart disease (MESH:D017202), weight loss (MESH:D015431), Bone (MESH:D001847), anti-phospholipid syndrome (MESH:D016736), osteomalacia (MESH:D010018), osteoporosis (MESH:D010024), arthritis (MESH:D001168), vascular calcification (MESH:D061205), hypocalcemia (MESH:D006996), back pain (MESH:D001416), mineral metabolism abnormalities (MESH:D008659), bone fragility (MESH:C536063), bone resorption (MESH:D001862), kidney failure (MESH:D051437), malignancy (MESH:D009369), osteoporotic (MESH:D058866), secondary hyperparathyroidism (MESH:D006962), CKD (MESH:D051436), chronic inflammation (MESH:D007249), skeletal injury (MESH:D014947), hyperparathyroidism (MESH:D006961), Fracture (MESH:D050723)
- **Chemicals:** alfacalcidol (MESH:C008088), Bisphosphonates (MESH:D004164), Calcium (MESH:D002118), alendronate (MESH:D019386), romosozumab (MESH:C557282), Denosumab (MESH:D000069448), teriparatide (MESH:D019379), ZOL (MESH:D000077211), vitamin D (MESH:D014807), phosphate (MESH:D010710), phosphorus (MESH:D010758)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12935734/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12935734/full.md

## References

2 references — full list in the complete paper: https://tomesphere.com/paper/PMC12935734/full.md

---
Source: https://tomesphere.com/paper/PMC12935734